CD274 and esophageal squamous cell carcinoma: Therefore, the national Comprehensive Cancer Network has suggested pembrolizumab combined with chemotherapy as a first-line therapy for both EAC and ESCC depending on the PD-L1 expression level (23), whereas pembrolizumab only suggested in ESCC patients as a second-line therapy based on KEYNOTE-181.